Narrator: This is Science Today. The delivery of therapeutic molecules across the blood-brain barrier may prove to be a major development in the treatment of ALS – a neurodegenerative disease also known as Lou Gehrig's disease.
Cleveland : Lou Gehrig's disease is a disease in which the muscles just stop working because the nerves that innervate them and signal them to contract die. It's a disease typically progressive over a time course of a few years and is almost always invariably fatal.
Narrator: Don Cleveland of the University of California , San Diego School of Medicine, helped design and test molecules known as antisense oligonucleotides and found that in the lab, when effective doses were delivered, far less of the protein that causes a hereditable form of ALS was produced.
Cleveland : We have no therapy that really slows the course of the disease. Therefore, we would argue that there is hope, real hope for bringing an effective therapy to ALS.
Narrator: For Science Today, I'm Larissa Branin.